-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2960 Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, artificial intelligence (AI), Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, aggressive lymphoma, Therapies, therapy sequence, Lymphoid Malignancies, Technology and Procedures, imaging, machine learning
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Juan Pablo Alderuccio, MD1, Russ A Kuker, MD2*, Isildinha M Reis, PhD3*, Muthiah Nachiappan, MD4*, Brad S. Kahl, MD5, Mehdi Hamadani, MD6, Weiyun Z. Ai, MD, PhD7, John Radford, MD, FRCPath, FMedSci8*, Melhem Solh, MD9, Kirit M. Ardeshna10, Brian T. Hess, MD11, Matthew A. Lunning, DO, FACP12, Pier Luigi Zinzani, MD, PhD13, Anastasios Stathis, MD14*, Carmelo Carlo-Stella, MD, PhD15, Eric Yu, PhD16*, Paolo F Caimi, MD17,18*, Deukwoo Kwon, PhD19*, Izidore S. Lossos, MD20, Fei Yang, PhD21* and Craig H. Moskowitz, MD22

1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL
2Division of Nuclear Medicine, University of Miami Miller School of Medicine, Miami
3Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
4Division of Nuclear Medicine, Sylvester Comprehensive Cancer Center, Miami
5Division of Oncology, Washington University School of Medicine in St. Louis, Saint Louis, MO
6The BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
7Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
8The Christie NHS Foundation Trust, Manchester Cancer Research Centre and Manchester Academic Health Science Centre, Manchester, United Kingdom
9BMT Group of Georgia, BMT Group of Georgia, Atlanta, GA
10Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
11Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
12Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE
13IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy
14Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, Switzerland
15Humanitas University and IRCCS Humanitas Research Hospital, Milan, Milano, Italy
16ADC Therapeutics America, Murray Hill, NJ
17Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
18Taussig Cancer Institute, Cleveland Clinic, Cleveland
19University of Miami, Miami, FL
20Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL
21Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miami
22Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

Introduction: Identification of new predictive biomarkers in relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) is essential for individualized treatment selection and optimization of outcomes. Metabolic tumor volume (MTV) is a strong prognostic factor in DLBCL, though, its value in patients treated with loncastuximab tesirine has not yet been explored. We investigated the impact of quantitative PET/CT data on treatment response and survival in patients treated with this compound.

Methods: In this post-hoc analysis, we reviewed screening PET/CT images of patients enrolled in the LOTIS-2 trial (NCT03589469). MTV was obtained by adding the metabolic volumes of all individual lesions using the 41% of SUVmax threshold. Total lesion glycolysis (TLG) was calculated as the product of MTV and SUVmean for all individual lesions. SUVmax, MTV and TLG were calculated on screening PET/CT images by a nuclear medicine (NM) radiologist using Hermes Affinity Viewer software. Values calculated by the first reader were independently confirmed by a second NM reader and a deep learning-aided automated method (Kuker R, et al. SNMMI 2022). We tested if these quantitative metrics presented as continuous variables, in the original scale and as log2-transformed data, could predict treatment response, event-free survival (EFS) and overall survival (OS). We also used an outcome-oriented method to determine cutpoints (c) as markers for risk-stratification. Internal validation based on bootstrap was performed to evaluate predictive performance of identified cutpoints. Optimism was calculated using mean of differences between AUC of bootstrap sample and AUC of original dataset. The optimism-corrected AUCs (ocAUC) was considered to take account of model overfitting. The goals of this study were to assess the impact of quantitative PET/CT metrics to predict complete metabolic response (CMR) (primary endpoint) and survival (secondary endpoints) after loncastuximab tesirine treatment. We grouped together patients with no metabolic response (NMR), disease progression (PD), and not evaluable (NE) due to similar survival.

Results: At the time of analysis, PET/CT images were available for review in 118 of the 145 patients enrolled. We first investigated the predictive value of PET/CT metrics to determine CMR. Patients achieving CMR exhibited significantly lower values in SUVmax, MTV and TLG (Table 1). We identified high interobserver agreement in MTV values.

As continuous variables, log2(SUVmax), log2(MTV) and log2(TLG) were predictive of failure to achieve CMR (1-unit increase odds ratio [OR]= 1.06, 95%CI 1.01-1.10, P=0.008, AUC=0.666; OR=1.52, 95%CI 1.22-1.89, P=0.002, AUC=0.744; and OR=1.49, 95%CI 1.23-1.80, P<.0001, AUC=0.758; respectively). We identified the cutpoints of SUVmax ≥17 (OR=3.94, 95%CI 1.62-9.58, P=0.002, ocAUC= 0.653), MTV ≥43ml (OR=6.82, 95%CI 2.51-18.51, P=0.0002, ocAUC=0.716) and TLG ≥434 (OR=6.84, 95%CI=2.61-17.89, P<.001, ocAUC=0.720) as predictors of failure to achieve CMR.

Next, we assessed the association of PET/CT metrics with EFS and OS. Median EFS & OS (months) by treatment response were: CMR= not reached (NR) (95%CI 14.2-NR) & NR (95%CI 16.2-NR); PMR= 3.4 (95%CI 2.8-7.4) & 11.2 (95%CI 7.1-16.4); NMR/PD= 1.4 (95%CI 1.3-2) & 5.8 (95%CI 2.6-6.9); (P<.0001) respectively. Again, log2(MTV) (hazard ratio (HR)=1.28, 95%CI 1.15-1.42, P<.0001 and HR=1.38, 95%CI 1.22-1.55, P<.0001) and log2(TLG) (HR=1.21, 95%CI 1.11-1.32, P<.0001 and HR=1.29, 95%CI 1.17-1.42, P<.0001) predicted shorter EFS and OS, respectively. log2(SUVmax) predicted only shorter OS (HR=1.02, 95%CI 1.00-1.03, P=0.033). We observed SUVmax ≥18 (EFS: HR=1.65, 95%CI 1.06-2.55, P=0.027 & OS: HR=1.7, 95%CI 1.06-2.75, P=0.029), MTV ≥68ml (EFS: HR=3.02, 95%CI 1.94-4.7, P<.0001 & OS: HR=3.26, 95%CI 2.05-5.19, P<.0001) and TLG ≥479 (EFS: HR=2.34, 95%CI 1.52-3.6, P=.0001 & OS: HR=2.46, 95%CI 1.54-3.91, P=.0001) as cutpoints associated with shorter survival.

Conclusion: In the present analysis we demonstrated the predictive impact of PET/CT data in rel/ref DLBCL retaining its risk-stratification power as continuous and categorical variables. MTV is an imaging biomarker extracted from routine PET/CT scans and enables individualized treatment selection identifying those patients that will benefit the most from loncastuximab tesirine.

Disclosures: Alderuccio: Pyramid: Consultancy; Agios: Consultancy; ADC Therapeutics: Consultancy, Research Funding. Kahl: ADT Therapeutics: Consultancy; AstraZeneca: Consultancy, Research Funding; Roche: Consultancy; Genentech: Consultancy, Research Funding; Abbvie: Consultancy, Research Funding; Pharmacyclics: Consultancy; MEI: Consultancy; AcertaPharma: Consultancy; Celgene/BMS: Consultancy, Research Funding; Beigene: Consultancy, Research Funding; Kite: Consultancy; Janssen: Consultancy; Incyte: Consultancy; Hutchmed: Consultancy, Research Funding; Seattle Genetics: Consultancy; TG Therapeutics: Consultancy; Genmab: Consultancy; Research To Practice: Speakers Bureau. Hamadani: BioGene: Speakers Bureau; Astellas Pharma: Research Funding; Legend Biotech: Consultancy; Kadmon: Consultancy; ADC Therapeutics: Consultancy, Research Funding, Speakers Bureau; Omeros: Consultancy; Abbvie: Consultancy; Takeda: Research Funding; Spectrum Pharmaceuticals: Research Funding; Sanofi Genzyme: Speakers Bureau; Gamida Cell: Consultancy; Novartis: Consultancy; AstraZeneca: Speakers Bureau; SeaGen: Consultancy; Genmab: Consultancy; MorphoSys: Consultancy; Kite: Consultancy; Incyte Corporation: Consultancy; Medical University of Wisconsin: Current Employment. Ai: Secura Bio: Consultancy; More Health: Consultancy; Kymera: Consultancy; Kite: Consultancy; AC therapeutics: Consultancy; Acrotech: Consultancy; BeiGene: Consultancy; Walking Fish: Consultancy. Radford: The University of Manchester and Christie Hospital NHS Foundation Trust: Current Employment; ADC Therapeutics: Consultancy, Current equity holder in private company, Current holder of stock options in a privately-held company, Honoraria, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria; Kite Pharma: Consultancy; Astrazenca: Current equity holder in private company, Current holder of stock options in a privately-held company. Solh: Partner Therapeutics: Research Funding; ADC Therapeutics: Research Funding. Ardeshna: Gilead: Honoraria; Novartis: Honoraria; BMS: Honoraria. Hess: Bristol-Myers Squibb: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; ADC Therapeutics: Consultancy. Lunning: Seattle Genetics: Consultancy; Nurix Therapeutics: Consultancy; Pharmacyclics: Consultancy; Morphosys: Consultancy; Acrotech: Consultancy; AbbVie: Consultancy; Fate Therapeutics: Consultancy; Astra-Zeneca: Consultancy; Diiachi-Sankyo: Consultancy; Janssen: Consultancy; Kite, a Gilead Company: Consultancy; ADC Therapeutics: Consultancy; Genmab: Consultancy; CURIS: Research Funding; Genentech: Consultancy; EUSA: Consultancy; TG Therapeutics: Consultancy; Astellas: Consultancy; BMS: Consultancy, Research Funding. Zinzani: Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Sandoz: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celltrion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kyowa Kirin: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Eusapharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Secura Bio: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; University of Bologna: Current Employment. Stathis: Bayer: Research Funding; ImmunoGen: Research Funding; Merck: Research Funding; Pfizer: Research Funding; Novartis: Research Funding; Roche: Research Funding; MEI Pharma: Research Funding; ADC-Therapeutics;: Research Funding; AbbVie: Other: travel grant; PharmaMar: Other: travel grant. Carlo-Stella: Karyopharm Therapeutics: Other: Consultancy/Advisory; Celgene/Bristol Myers Squibb: Other: Consultancy/Advisory; Takeda: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Scenic Biotech: Other: Consultancy/Advisory; Roche: Other: Consultancy/Advisory, Research Funding; ADC Therapeutics: Honoraria, Other: Consultancy/Advisory, Research Funding; AstraZeneca: Honoraria; Janssen Oncology: Honoraria; Merck Sharp & Dohme: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Other: Consultancy/Advisory, Research Funding. Yu: ADC Therapeutics: Current Employment, Current equity holder in private company, Current holder of stock options in a privately-held company. Caimi: ADC Therapeutics: Consultancy, Research Funding; Genentech: Research Funding; Kite Pharmaceuticals: Consultancy; Verastem: Consultancy; Seattle genetics: Consultancy; Amgen: Consultancy; TG Therapeutics: Consultancy; Celgene: Speakers Bureau. Lossos: LRF: Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; NCI: Research Funding. Moskowitz: Merck: Honoraria.

See more of: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH